FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have
the potential to be both more efficacious and safer than the currently available direct oral …

During the past decade, direct oral anticoagulants (DOACs) have advanced and simplified
the prevention and treatment of venous thromboembolism (VTE). However, there remains a …

Although anticoagulation therapy has evolved from non-specific drugs (ie, heparins and
vitamin K antagonists) to agents that directly target specific coagulation factors (ie, direct oral …

Anticoagulant drugs that are currently used to prevent and/or treat thrombosis have some
limitations that hinder their ability to meet specific clinical requirements. While these drugs …

Anticoagulants have been in use for nearly a century for the treatment and prevention of
venous and arterial thromboembolic disorders. The most dreaded complication of …

During the past decade, emergence of direct oral anticoagulants (DOACs) has drastically
improved the prevention of thrombosis. However, several unmet needs prevail in the field of …

The evolution of anticoagulation therapy, from vitamin K antagonists to the advent of direct
oral anticoagulants (DOACs) almost two decades ago, marks significant progress. Despite …

Bleeding is the dominant adverse event of anticoagulation and often discourages many
patients and physicians from starting treatment with anticoagulant drugs. The fact that factor …

Compared with vitamin K antagonists, the direct oral anticoagulants (DOACs) are simpler to
administer and are associated with less intracranial bleeding. Nonetheless, even with the …

In this review, we give an overview over observational and experimental studies supporting
factors XI and XII as targets for anticoagulant therapy. The majority of observational studies …